Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Clesrovimab for prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants during their first RSV season

5 October 2026

Condition

Respiratory

-

Published on 05 Oct 2026
Last Updated on 05 Oct 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended clesrovimab for inclusion on the MOH Subsidised Vaccine List (SVL) for prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract disease in infants during their first RSV season. The decision was based on the unfavourable cost effectiveness of clesrovimab compared with no immunisation.

Clesrovimab for prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants during their first RSV season (Published 5 Oct 2026) [PDF, 293.93 KB] (opens in new tab)

Plain English Summary

Lower respiratory tract disease occurs when there is an infection in the lungs or the airways. Respiratory syncytial virus (RSV) is a common cause of this type of infection in children under two years old. RSV spreads in a similar way to the common cold, through droplets from sneezing or coughing, or by touching surfaces contaminated with the virus. It usually causes mild symptoms, but it can sometimes lead to more serious illness when it infects the lungs (pneumonia), large airways (bronchitis) or small airways (bronchiolitis).

RSV is highly contagious and most children have an RSV infection by the age of two. A child’s first RSV infection is often the most severe. Symptoms of more serious illness can include coughing, wheezing, reduced appetite, irritability, shortness of breath and fever. Babies who are born prematurely, have certain lung or heart diseases, or have a weakened immune system are at higher risk of severe infection.

Clesrovimab is a biologic medicine (monoclonal antibody) that helps protect against severe RSV disease. It is given as an injection into a muscle (intramuscularly), usually at birth or before leaving hospital, to help protect infants during their first RSV season (typically within their first year of life).

Clesrovimab was not recommended for government subsidy for preventing illness from RSV infection because its benefits do not justify its cost. Other options are available to help prevent severe RSV infection. Your doctor can advise whether clesrovimab or another option may be suitable for your child.